Clinical Trials
4
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Rescues On Reperfusion Damage In Cerebral Infarction by Nelonemdaz
- Conditions
- Ischemic Stroke
- Interventions
- Drug: Neu2000KWL groupDrug: Placebo group
- First Posted Date
- 2021-09-10
- Last Posted Date
- 2022-09-26
- Lead Sponsor
- GNT Pharma
- Target Recruit Count
- 496
- Registration Number
- NCT05041010
- Locations
- 🇰🇷
Inje University Busan Paik Hospital, Busan, Korea, Republic of
🇰🇷Dong-A University Hospital, Busan, Korea, Republic of
🇰🇷Gyeongsang National University Hospital, Changwon, Korea, Republic of
Antioxidant and NMDA Receptor Blocker Wins Anoxic Brain Damage of KorEa OHCA Patients
- Conditions
- Cardiac Arrest
- Interventions
- Drug: Neu2000KWL High-dose groupDrug: Neu2000KWL Low-dose groupDrug: Placebo
- First Posted Date
- 2018-08-29
- Last Posted Date
- 2019-03-06
- Lead Sponsor
- GNT Pharma
- Target Recruit Count
- 150
- Registration Number
- NCT03651557
- Locations
- 🇰🇷
Kyungpook National University Hospital, Daegu, Korea, Korea, Republic of
🇰🇷Soonchunhyang University Bucheon Hospital, Bucheon, Korea, Republic of
🇰🇷Pusan National University Hospital, Busan, Korea, Republic of
Safety and Optimal Neuroprotection of neu2000 in Ischemic Stroke With Endovascular reCanalizion (SONIC)
- Conditions
- Ischemic Stroke
- Interventions
- Drug: Neu2000KWL Low-does groupDrug: PlaceboDrug: Neu2000KWL High-does group
- First Posted Date
- 2016-07-13
- Last Posted Date
- 2017-07-13
- Lead Sponsor
- GNT Pharma
- Target Recruit Count
- 210
- Registration Number
- NCT02831088
- Locations
- 🇰🇷
Chungbuk National University Hospital, Cheongju, Korea, Republic of
🇰🇷Keimyung University Dongsan Medical Center, Daegu, Korea, Republic of
🇰🇷Kyungpook National University Hospital, Daegu, Korea, Republic of
News
GNT Pharma Advances First-in-Class Dual-Action Stroke Therapy Nelonemdaz to Global Phase 3 Trials
GNT Pharma received regulatory approval from South Korea's MFDS to initiate global Phase 3 clinical trials for Nelonemdaz, the world's first dual-action neuroprotectant for ischemic stroke treatment.
GNT Pharma's Nelonemdaz Shows Promise in Improving Stroke Outcomes with Early Administration
GNT Pharma's Nelonemdaz, combined with thrombectomy, demonstrates significant improvements in stroke patient outcomes when administered early.
Ischemic Stroke Pipeline Shows Promise with Novel Therapies in Development
Over 55 potential drugs for ischemic stroke are currently in the pipeline, targeting novel treatment approaches.